Impact of antibiotics on the intestinal microbiota and on the treatment of Shiga-toxin-producing Escherichia coli and Salmonella infections

Current Pharmaceutical Design

Volumn 20, Issue 28, 2014, Pages 4535-4548

  Szych, Jolanta ^a   Wołkowicz, Tomasz ^a   La Ragione, Roberto ^b,c   Madajczak, Grzegorz ^a  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

^b VETERINARY LABORATORIES AGENCY   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Antibiotics; Asymptomatic carriage; EHEC; Escherichia coli; HUS; Microbiota; Salmonella; Side effect; STEC

Indexed keywords

ANTIBIOTIC AGENT; VIRULENCE FACTOR; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; DYSBIOSIS; ESCHERICHIA COLI INFECTION; FATALITY; GASTROINTESTINAL TRACT; HEMOLYTIC UREMIC SYNDROME; HIGH RISK POPULATION; HOMEOSTASIS; HOST PATHOGEN INTERACTION; HUMAN; INTESTINE FLORA; MACROPHAGE; MURINE MODEL; NONHUMAN; PARATYPHOID FEVER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SALMONELLA; SALMONELLOSIS; SEROTYPE; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SHIGA TOXIN PRODUCING ESCHERICHIA COLI INFECTION; TYPHOID FEVER; ANIMAL; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; HEMOLYTIC-UREMIC SYNDROME; INTESTINE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MICROFLORA; RISK; SALMONELLA INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI INFECTIONS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INTESTINES; MICROBIOTA; RISK; SALMONELLA INFECTIONS; SHIGA-TOXIGENIC ESCHERICHIA COLI;

EID: 84904761913     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660730     Document Type: Review

References (174)

1. Peterson J, Garges S, Giovanni M, et al. The NIH Human Microbiome Project. Genome Res 2009; 19(12): 2317-23.
2. Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad Sci USA 2003; 100(18): 10452-9.
3. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104(34): 13780-5.
4. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006; 7(7): 688-93.
5. Swidsinski A, Loening-Baucke V, Lochs H, Hale LP. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterology 2005; 11(8): 1131-40.
6. Mändar R, Mikelsaar M. Transmission of Mother's Microflora to the Newborn at Birth. Neonatology 1996; 69(1): 30-5.
7. Huurre A, Kalliomäki M, Rautava S, Rinne M, Salminen S, Isolauri E. Mode of Delivery-Effects on Gut Microbiota and Humoral Immunity. Neonatology 2008; 93(4): 236-40.
8. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clinical Nutrition 1999; 69(5): 1035S-1045S.
9. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312(5778): 1355-9.
10. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005; 308(5728): 1635-8.
11. Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut Microbiota in Health and Disease. Physiological Rev 2010; 90 (3): 859-904.
12. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007; 449(7164): 804-10.
13. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009 Jan 22; 457(7228): 480-4.
14. Brisbin JT, Gong J, Sharif S. Interactions between commensal bacteria and the gut-associated immune system of the chicken. Animal Health Research Rev 2008; 9(1): 101-10.
15. Round JL, Lee SM, Li J, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011; 332(6032): 974-7.
16. Brandl K, Plitas G, Schnabl B, DeMatteo RP, Pamer EG. MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med 2007; 204(8): 1891-900.
17. Blum S, Schiffrin EJ. Intestinal microflora and homeostasis of the mucosal immune response: implications for probiotic bacteria? Curr Issues Intestinal Microbiol 2003; 4(2): 53-60.
18. Hooper L V. Commensal Host-Bacterial Relationships in the Gut. Science 2001; 292(5519): 1115-8.
19. Liu CH, Lee SM, Vanlare JM, Kasper DL, Mazmanian SK. Regulation of surface architecture by symbiotic bacteria mediates host colonization. Proc Natl Acad Sci USA 2008; 105(10): 3951-6.
20. Are A, Aronsson L, Wang S, et al. Enterococcus faecalis from newborn babies regulate endogenous PPARgamma activity and IL-10 levels in colonic epithelial cells. Proc Natl Acad Sci USA 2008; 105(6): 1943-8.
21. Pacheco AR, Curtis MM, Ritchie JM, et al. Fucose sensing regulates bacterial intestinal colonization. Nature 2012; 492(7427): 113-7.
22. Ivanov II, Littman DR. Modulation of immune homeostasis by commensal bacteria. Current Opinion in Microbiology 2011; 14(1): 106-14.
23. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139(3): 485-98.
24. Heczko U, Abe A, Finlay BB. Segmented filamentous bacteria prevent colonization of enteropathogenic Escherichia coli O103 in rabbits. The J Infectious Diseases. Oxford University Press; 2000 Mar 1; 181(3): 1027-33.
25. Mangell P, Lennernäs P, Wang M, et al. Adhesive capability of Lactobacillus plantarum 299v is important for preventing bacterial translocation in endotoxemic rats. Acta Pathologica, Microbiologica, et Immunologica Scandinavica 2006; 114(9): 611-8.
26. Sekirov I, Tam NM, Jogova M, et al. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. Infect. Immun 2008; 76(10): 4726-36.
27. Gantois I, Ducatelle R, Pasmans F, et al. Butyrate specifically down-regulates Salmonella pathogenicity island 1 gene expression. Appl. Environ. Microbiol 2006; 72(1): 946-9.
28. Hughes DT, Terekhova DA, Liou L, et al. Chemical sensing in mammalian host-bacterial commensal associations. Proc Natl Acad Sci USA 2010; 107(21): 9831-6.
29. Corr SC, Gahan CGM, Hill C. Impact of selected Lactobacillus and Bifidobacterium species on Listeria monocytogenes infection and the mucosal immune response. FEMS Immunol. Med. Microbiol 2007; 50(3): 380-8.
30. Alakomi H-L, Skytta E, Saarela M, Mattila-Sandholm T, Latva Kala K, Helander IM. Lactic Acid Permeabilizes Gram-Negative Bacteria by Disrupting the Outer Membrane. Appl. Environ. Microbiol 2000; 66(5): 2001-5.
31. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134(2): 577-94.
32. Kullberg MC, Andersen JF, Gorelick PL, et al. Induction of colitis by a CD4+ T cell clone specific for a bacterial epitope. Proc Natl Acad Sci USA 2003; 100(26): 15830-5.
33. Andoh A, Imaeda H, Aomatsu T, et al. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterology. Springer Japan; 2011; 46(4): 479-86.
34. Sepehri S, Khafipour E, Bernstein CN, et al. Characterization of Escherichia coli isolated from gut biopsies of newly diagnosed patients with inflammatory bowel disease. Inflammatory Bowel Diseases 2011; 17(7): 1451-63.
35. Jiang Z-D, Ke S, Palazzini E, Riopel L, Dupont H. In vitroActivity and Fecal Concentration of Rifaximin after Oral Administration. Antimicrob. Agents Chemother 2000; 44(8): 2205-6.
36. Croswell A, Amir E, Teggatz P, Barman M, Salzman NH. Prolonged impact of antibiotics on intestinal microbial ecology and susceptibility to enteric Salmonella infection. Infect. Immun 2009; 77(7): 2741-53.
37. Levy J. The effects of antibiotic use on gastrointestinal function. Am J Gastroenterol 2000; 95(1): S8-S10.
38. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infectious Diseases 2001; 1(2): 101-14.
39. Antonopoulos DA, Huse SM, Morrison HG, Schmidt TM, Sogin ML, Young VB. Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect. Immun 2009; 77(6): 2367-75.
40. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. The ISME journal 2007; 1(1): 56-66.
41. Merrell DS, Camilli A. The cadA gene of Vibrio cholerae is induced during infection and plays a role in acid tolerance. Mol Microbiol 1999; 34(4): 836-49.
42. Wells CL, Jechorek RP, Erlandsen SL. Evidence for the Translocation of Enterococcus faecalis across the Mouse Intestinal Tract. J Infectious Diseases 1990; 162(1): 82-90.
43. Wells CL, Maddaus MA, Reynolds CM, Jechorek RP, Simmons RL. Role of anaerobic flora in the translocation of aerobic and facultatively anaerobic intestinal bacteria. Infect. Immun 1987; 55(11): 2689-94.
44. Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therapeutic Advances in Gastroenterology 2013; 6(1): 53-68.
45. Tanaka S, Kobayashi T, Songjinda P, et al. Influence of antibiotic exposure in the early postnatal period on the development of intestinal microbiota. FEMS Immunol Med Microbiol 2009; 56(1): 80-7.
46. Kozyrskyj AL, Ernst P, Becker AB. Increased risk of childhood asthma from antibiotic use in early life. Chest 2007; 131(6): 1753-9.
47. Sjölund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Annals of Internal Medicine. University Hospital Uppsala, Uppsala, Sweden.; 2003; 139(6): 483-7.
48. Löfmark S, Jernberg C, Jansson JK, Edlund C. Clindamycininduced enrichment and long-term persistence of resistant Bacteroides spp. and resistance genes. The J Antimicrobial Chemotherapy 2006; 58(6): 1160-7.
49. Sjölund M, Tano E, Blaser MJ, Andersson DI, Engstrand L. Persistence of resistant Staphylococcus epidermidis after single course of clarithromycin. Emerging Infectious Diseases 2005; 11(9): 1389-93.
50. Nyberg SD, Osterblad M, Hakanen AJ, et al. Long-term antimicrobial resistance in Escherichia coli from human intestinal microbiota after administration of clindamycin. Scandinavian J Infectious Diseases 2007; 39(6-7): 514-20.
51. Lester CH, Frimodt-Møller N, Sørensen TL, Monnet DL, Hammerum AM. In vivotransfer of the vanA resistance gene from an Enterococcus faecium isolate of animal origin to an E. faecium isolate of human origin in the intestines of human volunteers. Antimicrob. Agents Chemother 2006; 50(2): 596-9.
52. Salyers AA, Gupta A, Wang Y. Human intestinal bacteria as reservoirs for antibiotic resistance genes. Trends Microbiol 2004; 12(9): 412-6.
53. Scott KP. The role of conjugative transposons in spreading antibiotic resistance between bacteria that inhabit the gastrointestinal tract. Cell Mol Life Sci Birkhäuser Verlag 2002; 59(12): 2071-82.
54. Shoemaker NB, Vlamakis H, Hayes K, Salyers AA. Evidence for extensive resistance gene transfer among Bacteroides spp. and among Bacteroides and other genera in the human colon. Appl Environ Microbiol 2001; 67(2): 561-8.
55. Karami N, Martner A, Enne VI, Swerkersson S, Adlerberth I, Wold AE. Transfer of an ampicillin resistance gene between two Escherichia coli strains in the bowel microbiota of an infant treated with antibiotics. J Antimicrobial Chemotherap 2007; 60(5): 1142-5.
56. DuPont HL. Approach to the patient with infectious colitis. Current Opinion in Gastroenterology 2012; 28(1): 39-46.
57. Alpers K, Werber D, Frank C, et al. Sorbitol-fermenting enterohaemorrhagic Escherichia coli O157: H-causes another outbreak of haemolytic uraemic syndrome in children. Epidemiology and Infection 2009; 137(3): 389-95.
58. Schimmer B, Nygard K, Eriksen HM, et al. Outbreak of haemolytic uraemic syndrome in Norway caused by stx2-positive Escherichia coli O103: H25 traced to cured mutton sausages. BMC Infectious Diseases 2008; 8: 41.
59. Manning SD, Motiwala AS, Springman AC, et al. Variation in virulence among clades of Escherichia coli O157: H7 associated with disease outbreaks. Proc Natl Acad Sci USA 2008; 105(12): 4868-73.
60. Raguenaud M, Hello S Le, Salah S. Epidemiological and microbiological investigation of a large outbreak of monophasic Salmonella Typhimurium 4, 5, 12: i:-in schools associated with imported. beef in poifiers, France, October 2010. Eurosurveillance 2012; 17(40): 1-7.
61. Mossong J, Marques P, Ragimbeau C, et al. Outbreaks of monophasic Salmonella enterica serovar 4,[5], 12: i:-in Luxembourg, 2006. Eurosurveillance 2007; 12(6): 156-8.
62. Scheutz F, Nielsen EM, Frimodt-Møller J, et al. Characteristics of the enteroaggregative Shiga toxin/verotoxin-producing Escherichia coli O104: H4 strain causing the outbreak of haemolytic uraemic syndrome in Germany, May to June 2011. Eurosurveillance 2011 Jan; 16(24).
63. Holtz LR, Neill MA, Tarr PI. Acute bloody diarrhea: a medical emergency for patients of all ages. Gastroenterology 2009; 136(6): 1887-98.
64. Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne Illness Acquired in the United States-Major Pathogens. Emerging Infectious Diseases 2011; 17(1): 7-15.
65. EFSA. Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 2010. EFSA Journal 2012; 10(3): 1-442.
66. Jores J, Rumer L, Wieler LH. Impact of the locus of enterocyte effacement pathogenicity island on the evolution of pathogenic Escherichia coli. International J Med Microbiol 2004; 294(2-3): 103-13.
67. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol 2004; 2(2): 123-40.
68. Johnson RP, Clarke RC, Wilson JB, et al. Growing Concerns and Recent Outbreaks Involving Non-O157: H7 Serotypes of Verotoxigenic Escherichia coli. J Food Protection 1996; 59(10): 1112-22.
69. Strockbine NA, Wells JG, Bopp CA, Barrett TJ. Overview of detection and subtyping methods. In: Kaper JB, O'Brien AD, editors. Escherichia coli O157: H7 and Other Shiga Toxinproducing E. coli Strains. Washington, D.C. Am Soc Microbiol Press 1998; p: 331-56.
70. Johnson KE, Thorpe CM, Sears CL. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. Clinical Infectious Diseases 2006; 43(12): 1587-95.
71. Gould LH, Bopp C, Strockbine N, et al. Recommendations for diagnosis of shiga toxin-producing Escherichia coli infections by clinical laboratories. Department of Health and Human Services, Centers for Disease Control and Prevention; 2009.
72. Mellmann A, Bielaszewska M, Köck R, et al. Analysis of collection of hemolytic uremic syndrome-associated enterohemorrhagic Escherichia coli. Emerging Infectious Diseases 2008; 14(8): 1287-90
73. Buvens G, De Gheldre Y, Dediste A, et al. Incidence and virulence determinants of verocytotoxin-producing Escherichia coli infections in the Brussels-Capital Region, Belgium, in 2008-2010. J Clin Microbiol 2012; 50(4): 1336-45.
74. Anjum MF, Mafura M, Slickers P, et al. Pathotyping Escherichia coli by using miniaturized DNA microarrays. Appl Environ Microbiol 2007; 73(17): 5692-7.
75. Bruant G, Maynard C, Bekal S, et al. Development and validation of an oligonucleotide microarray for detection of multiple virulence and antimicrobial resistance genes in Escherichia coli. Appl Environ Microbiol 2006; 72(5): 3780-4.
76. Bekal S, Brousseau R, Masson L, Prefontaine G, Fairbrother J, Harel J. Rapid identification of Escherichia coli pathotypes by virulence gene detection with DNA microarrays. J Clin Microbiol 2003; 41(5): 2113-25.
77. Gerritzen A, Wittke J-W, Wolff D. Rapid and sensitive detection of Shiga toxin-producing Escherichia coli directly from stool samples by real-time PCR in comparison to culture, enzyme immunoassay and Vero cell cytotoxicity assay. Clinical Laboratory 2011; 57(11-12): 993-8.
78. Gault G, Weill FX, Mariani-Kurkdjian P, et al. Outbreak of haemolytic uraemic syndrome and bloody diarrhoea due to Escherichia coli O104: H4, south-west France, June 2011. Eurosurveillance 2011; 16(26): 4-6.
79. Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shigatoxin-producing Escherichia coli O104: H4 outbreak in Germany. The New England J Medicine 2011; 365(19): 1771-80.
80. Goulet V, Hedberg C, Le Monnier A, De Valk H. Increasing incidence of listeriosis in France and other European countries. Emerging Infectious Diseases 2008; 14(5): 734-40.
81. Soborg B, Lassen S, Müller L. A verocytotoxin-producing E. coli outbreak with a surprisingly high risk of haemolytic uraemic syndrome, Denmark, September-October 2012. Eurosurveillance 2013; 18(2).
82. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 2005; 295(6-7): 405-18.
83. Tarr PI, Gordon C a, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365(9464): 1073-86.
84. Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. The J Infectious Diseases 2002; 186(4): 493-500.
85. Gould LH, Jordan JG, Dunn J, Apostol M, Griffin PM. Postdiarrheal hemolytic uremic syndrome in persons aged 65 and older in foodnet sites, 2000-2006. J Am Geriatrics Soc 2011; 59(2): 366-8.
86. Persson S, Olsen KEP, Ethelberg S, Scheutz F. Subtyping method for Escherichia coli shiga toxin (verocytotoxin) 2 variants and correlations to clinical manifestations. J Clin Microbiol 2007; 45(6): 2020-4.
87. Bielaszewska M, Mellmann A, Bletz S, et al. Enterohemorrhagic Escherichia coli O26: H11/H-: A New Virulent Clone Emerges in Europe. Clinical Infectious Diseases 2013 Feb 1
88. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998; 11(1): 142-201.
89. Scheutz F, Teel LD, Beutin L, et al. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J Clin Microbiol 2012; 50(9): 2951-63.
90. O'Brien A, Newland J, Miller S, Holmes R, Smith H, Formal S. Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. Science 1984; 226(4675): 694-6.
91. Herold S, Karch H, Schmidt H. Shiga toxin-encoding bacteriophages--genomes in motion. International J Medical Microbiology 2004 Sep; 294(2-3): 115-21.
92. Waldor MK, Friedman DI. Phage regulatory circuits and virulence gene expression. Curr Opinion Microbiol 2005; 8(4): 459-65.
93. Wagner PL, Neely MN, Zhang X, Acheson DW, Waldor MK, Friedman DI. Role for a phage promoter in Shiga toxin 2 expression from a pathogenic Escherichia coli strain. J Bacteriol 2001; 183(6): 2081-5.
94. Schmidt H. Shiga-toxin-converting bacteriophages. Res Microbiol 2001; 152(8): 687-95.
95. Mauro SA, Koudelka GB. Shiga toxin: expression, distribution, and its role in the environment. Toxins. Molecular Diversity Preservation International; 2011; 3(6): 608-25.
96. Schmidt H, Kernbach C, Karch H. Analysis of the EHEC hly operon and its location in the physical map of the large plasmid of enterohaemorrhagic Escherichia coli O157: H7. Microbiology 1996; 142(4): 907-14.
97. Law D, Kelly J. Use of heme and hemoglobin by Escherichia coli O157 and other Shiga-like-toxin-producing E. coli serogroups. Infect Immun 1995; 63(2): 700-2.
98. Jürgens D, Ozel M, Takaisi-Kikuni NB. Production and characterization of Escherichia coli enterohemolysin and its effects on the structure of erythrocyte membranes. Cell Biol Int 2002; 26(2): 175-86.
99. Beutin L, Montenegro MA, Orskov I, et al. Close association of verotoxin (Shiga-like toxin) production with enterohemolysin production in strains of Escherichia coli. J Clin Microbiol 1989; 27(11): 2559-64.
100. Zhang X, Cheng Y, Xiong Y, et al. Enterohemorrhagic Escherichia coli specific enterohemolysin induced IL-1β in human macrophages and EHEC-induced IL-1β required activation of NLRP3 inflammasome. PloS One 2012; 7(11): e50288.
101. Surette MG, Miller MB, Bassler BL. Quorum sensing in Escherichia coli, Salmonella typhimurium, and Vibrio harveyi: a new family of genes responsible for autoinducer production. Proc Natl Acad Sci USA 1999; 96(4): 1639-44.
102. Sperandio V, Torres AG, Giron JA, Kaper JB. Quorum Sensing Is a Global Regulatory Mechanism in Enterohemorrhagic Escherichia coli O157: H7. J. Bacteriol 2001; 183(17): 5187-97.
103. Sperandio V, Torres AG, Jarvis B, Nataro JP, Kaper JB. Bacteriahost communication: the language of hormones. Proc Natl Acad Sci USA 2003; 100(15): 8951-6.
104. Berin MC, Darfeuille-Michaud A, Egan LJ, Miyamoto Y, Kagnoff MF. Role of EHEC O157: H7 virulence factors in the activation of intestinal epithelial cell NF-κB and MAP kinase pathways and the upregulated expression of interleukin 8. Cell. Microbiol 2002; 4(10): 635-48.
105. Farfan MJ, Cantero L, Vergara A, Vidal R, Torres AG. The long polar fimbriae of STEC O157: H7 induce expression of proinflammatory markers by intestinal epithelial cells. Veterinary Immunology and Immunopathology 2012 Sep 26
106. Wagner PL, Acheson DW, Waldor MK. Human neutrophils and their products induce Shiga toxin production by enterohemorrhagic Escherichia coli. Infect. Immun 2001; 69(3): 1934-7.
107. Betz J, Bielaszewska M, Thies A, et al. Shiga toxin glycosphingolipid receptors in microvascular and macrovascular endothelial cells: differential association with membrane lipid raft microdomains. J. Lipid Res 2011; 52(4): 618-34.
108. Müthing J, Schweppe CH, Karch H, Friedrich AW. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Thromb. Haemostasis 2009; 101(2): 252-64.
109. Bauwens A, Betz J, Meisen I, Kemper B, Karch H, Müthing J. Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature. Cell Mol Life Sci 2013; 70(3): 425-57.
110. Utsunomiya I, Ren J, Taguchi K, et al. Immunohistochemical detection of verotoxin receptors in nervous system. Brain Res Protocols 2001; 8(2): 99-103.
111. O'Loughlin E V, Robins-Browne RM. Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells. Microbes Infection 2001; 3(6): 493-507.
112. Johannes L, Römer W. Shiga toxins--from cell biology to biomedical applications. Nat Rev Microbiol 2010; 8(2): 105-16.
113. Brigotti M, Caprioli A, Tozzi AE, et al. Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome. J Clin Microbiol 2006; 44(2): 313-7.
114. Livny J, Friedman DI. Characterizing spontaneous induction of Stx encoding phages using a selectable reporter system. Mol Microbiol 2004; 51(6): 1691-704.
115. Gamage SD, Strasser JE, Chalk CL, Weiss AA. Nonpathogenic Escherichia coli can contribute to the production of Shiga toxin. Infect Immun 2003; 71(6): 3107-15.
116. De Sablet T, Chassard C, Bernalier-Donadille A, Vareille M, Gobert AP, Martin C. Human microbiota-secreted factors inhibit shiga toxin synthesis by enterohemorrhagic Escherichia coli O157: H7. Infect Immun 2009; 77(2): 783-90.
117. Loś JM, Loś M, Wegrzyn A, Wegrzyn G. Hydrogen peroxidemediated induction of the Shiga toxin-converting lambdoid prophage ST2-8624 in Escherichia coli O157: H7. FEMS Immunol. Med Microbiol 2010; 58(3): 322-9.
118. Kimmitt PT, Harwood CR, Barer MR. Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerging Infectious Diseases. 6(5): 458-65.
119. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157: H7 infections. New Eng J Med 2000; 342(26): 1930-6.
120. Michino H, Araki K, Minami S, et al. Massive Outbreak of Escherichia coli O157: H7 Infection In Schoolchildren in Sakai City, Japan, Associated with Consumption of White Radish Sprouts. Am J Epidemiol 1999; 150(8): 787-96.
121. Ikeda K, Ida O, Kimoto K, Takatorige T, Nakanishi N, Tatara K. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157: H7 infection. Clinical Nephrol 1999; 52(6): 357-62.
122. Shiomi M, Togawa M, Fujita K, Murata R. Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157: H7. Pediatrics Int 1999; 41(2): 228-32.
123. Lee JH, Stein BD. Antimicrobials effective for inhibition of enterohaemorrhagic Escherichia coli strains O26, O111, and O157 and their effects on Shiga toxin releases. J Microbiology and Biotechnology. Veterinary Public Health, College of Veterinary Medicine and Bio-Safety Research Institute, Chonbuk National University, Jeonju 561-756, Korea. johnhlee@chonbuk. ac. kr; 2009; 19(10): 1238-43.
124. Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MK, Acheson DW. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infectious Diseases 2000; 181(2): 664-70.
125. Nakagawa S, Kojio S, Taneike I, et al. Inhibitory action of telithromycin against Shiga toxin and endotoxin. Biochemical and Bophysical Research Communications 2003; 310(4): 1194-9.
126. Rahal EA, Kazzi N, Sabra A, Abdelnoor AM, Matar GM. Decrease in Shiga toxin expression using a minimal inhibitory concentration of rifampicin followed by bactericidal gentamicin treatment enhances survival of Escherichia coli O157: H7-infected BALB/c mice. Ann Clin Microbiol Antimicrobials 2011; 10: 34.
127. Grif K, Dierich MP, Karch H, Allerberger F. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infectious Diseases 1998; 17(11): 761-6.
128. Bielaszewska M, Mellmann A, Zhang W, et al. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infectious Diseases 2011; 11(9): 671-6.
129. Brzuszkiewicz E, Thürmer A, Schuldes J, et al. Genome sequence analyses of two isolates from the recent Escherichia coli outbreak in Germany reveal the emergence of a new pathotype: EnteroAggregative-Haemorrhagic Escherichia coli (EAHEC). Arch Microbiol 2011; 193(12): 883-91.
130. German Society of Infectious Diseases. EHEC infection and antibiotic therapy [Internet] 2011 [cited 2013 Mar 27]. Available from: http: //www.dgi-net.de/images/stories/DGIposition_paper_EHECantibiotics_English_version_plus_references _20110604.pdf
131. Bielaszewska M, Idelevich EA, Zhang W, et al. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104: H4 strain. Antimicrob. Agents Chemother 2012; 56(6): 3277-82.
132. Corogeanu D, Willmes R, Wolke M, Plum G, Utermöhlen O, Krönke M. Therapeutic concentrations of antibiotics inhibit Shiga toxin release from enterohemorrhagic E. coli O104: H4 from the 2011 German outbreak. BMC Microbiol 2012; 12: 160.
133. Nitschke M, Sayk F, Härtel C, et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104: H4. The J Am Med Assoc 2012; 307(10): 1046-52.
134. Menne J, Nitschke M, Stingele R, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104: H4 induced haemolytic uraemic syndrome: case-control study. British Med J 2012; 345(jul19 1): e4565-e4565.
135. Januszkiewicz A, Szych J, Rastawicki W, Wołkowicz T, Chróst A, Leszczyłska B, et al. Molecular epidemiology of a household outbreak of Shiga-toxin-producing Escherichia coli in Poland due to secondary transmission of STEC O104: H4 from Germany. J Med Microbiol 2012; 61(Pt 4): 552-8.
136. L'Abée-Lund TM, Jørgensen HJ, O'Sullivan K, et al. The highly virulent 2006 Norwegian EHEC O103: H25 outbreak strain is related to the 2011 German O104: H4 outbreak strain. PloS One 2012; 7(3): e31413.
137. Hiroi M, Takahashi N, Harada T, et al. Serotype, Shiga Toxin (Stx) Type, and Antimicrobial Resistance of Stx-Producing Escherichia coli Isolated from Humans in Shizuoka Prefecture, Japan (2003-2007). Japanese J Infectious Diseases 2012; 65(3): 198-202.
138. Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawkins AT, Snyder MJ. Typhoid fever: pathogenesis and immunologic control. New Eng J Med 1970; 283(13): 686-91.
139. Chiu C, Su L-H, Chu C. Salmonella enterica Serotype Choleraesuis: Epidemiology, Pathogenesis, Clinical Disease, and Treatment. Clin Microbiol Rev 2004; 17(2): 311-22.
140. Chen YH, Chen TP, Lu PL, et al. Salmonella choleraesuis bacteremia in southern Taiwan. The Kaohsiung J Medical Sciences. Division of Infectious Diseases, Kaohsiung Medical College, Kaohsiung City, Taiwan, Republic of China.; 1999; 15(4): 202-8.
141. European Centre for Disease Prevention and Control. Salmonellosis. Annual Epidemiological Report Reporting on 2010 Surveillance Data and 2011 Epidemic Intelligence Data 2012. Stockholm: ECDC; 2013; p: 102-6.
142. European Centre for Disease Prevention and Control. Typhoid/paratyphoid fever. Annual Epidemiological Report Reporting on 2010 Surveillance Data and 2011 Epidemic Intelligence Data 2012. Stockholm: ECDC 2013; p: 122-5.
143. Ahmer BMM, Gunn JS. Interaction of Salmonella spp. with the Intestinal Microbiota. Frontiers Microbiol 2011; 2(May): 101.
144. Zihler A, Le Blay G, De Wouters T, et al. In vitroinhibition activity of different bacteriocin-producing Escherichia coli against Salmonella strains isolated from clinical cases. Letters in Applied Microbiology. Blackwell Publishing Ltd; 2009; 49(1): 31-8.
145. Guo L, Lim KB, Poduje CM, et al. Lipid A acylation and bacterial resistance against vertebrate antimicrobial peptides. Cell 1998; 95(2): 189-98.
146. Weinstein DL, O'Neill BL, Hone DM, Metcalf ES. Differential Early Interactions between Salmonella enterica Serovar Typhi and Two Other Pathogenic Salmonella Serovars with Intestinal Epithelial Cells. Infect Immun 1998; 66(5): 2310-8.
147. Ishibashi Y, Arai T. A possible mechanism for host-specific pathogenesis of Salmonella serovars. Microbial Pathogenesis 1996; 21(6): 435-46.
148. Vladoianu I-R, Chang HR, Pechère J-C. Expression of host resistance to Salmonella typhi and Salmonella typhimurium: bacterial survival within macrophages of murine and human origin. Microbial Pathogenesis 1990; 8(2): 83-90.
149. Santos RL, Zhang S, Tsolis RM, Kingsley R A, Garry Adams L, Bäumler AJ. Animal models of Salmonella infections: enteritis versus typhoid fever. Microbes and Infection 2001; 3(14-15): 1335-44.
150. Grimont PAD, Weill FX. Antigenic formulae of the Salmonella serovars. 9th ed. WHO Collaborating Centre for Reference and Research on Salmonella, Institut Pasteur, Paris, France. Paris: WHO Collaborating Centre for Reference and Research on Salmonella, Institut Pasteur; 2007.
151. Selander R, Smith N, Li J. Molecular evolutionary genetics of the cattle-adapted serovar Salmonella dublin. J. Bacteriol 1992; 174(11).
152. Seth-Smith HMB. SPI-7: Salmonella's Vi-Encoding Pathogenicity Island. The J Infection in Developing Countries 2008; 2(04).
153. Szu SC, Li XR, Stonea L, Robbins JB. Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect. Immun 1991; 59(12): 4555-61.
154. Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet 2005; 366(9487): 749-62.
155. Wain J, House D, Parkhill J, Parry C, Dougan G. Unlocking the genome of the human typhoid bacillus. Lancet Infectious Diseases 2002; 2(3): 163-70.
156. Stecher B, Denzler R, Maier L, et al. Gut inflammation can boost horizontal gene transfer between pathogenic and commensal Enterobacteriaceae. Proc Natl Acad Sci USA 2012; 109(4): 1269-74.
157. Gullberg E, Cao S, Berg OG, et al. Selection of resistant bacteria at very low antibiotic concentrations. Lipsitch M, editor. PloS Pathogens. Public Library of Science; 2011; 7(7): e1002158.
158. Schmieger H, Schicklmaier P. Transduction of multiple drug resistance of Salmonella enterica serovar typhimurium DT104. FEMS Microbiol. Lett 1999; 170(1): 251-6.
159. Woodward TE, Smadel JE, Ley HL. Chloramphenicol and other antibiotics in the treatment of typhoid fever and typhoid carriers. J Clin Investigation 1950; 29(1): 87-99.
160. Effa EE, Lassi ZS, Critchley JA, et al. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Systematic Rev 2011; (10): CD004530.
161. Zaki SA, Karande S. Multidrug-resistant typhoid fever: a review. J Infection Developing Countries 2011; 5(05): 83-90.
162. Phan M-D, Kidgell C, Nair S, et al. Variation in Salmonella enterica serovar typhi IncHI1 plasmids during the global spread of resistant typhoid fever. Antimicrob. Agents Chemother 2009; 53(2): 716-27.
163. Renuka K, Sood S, Das BK, Kapil A. High-level ciprofloxacin resistance in Salmonella enterica serotype Typhi in India. J Med Microbiol 2005; 54(Pt 10): 999-1000.
164. Antunes P, Mourão J, Machado J, Peixe L. First description of qnrS1-IncN plasmid in a ST11 Salmonella Enteritidis clinical isolate from Portugal. Diagnostic Microbiology and Infectious Disease. Elsevier Inc 2011; 69(4): 463-5.
165. González-Sanz R, Herrera-León S, De la Fuente M, Arroyo M, Echeita MA. Emergence of extended-spectrum beta-lactamases and AmpC-type beta-lactamases in human Salmonella isolated in Spain from 2001 to 2005. J Antimicrobial Chemotherap 2009; 64(6): 1181-6.
166. Veldman K, Van Pelt W, Mevius D. First report of qnr genes in Salmonella in The Netherlands. J Antimicrobial Chemotherapy 2008; 61(2): 452-3.
167. Torpdahl M, Hammerum AM, Zachariasen C, Nielsen EM. Detection of qnr genes in Salmonella isolated from humans in Denmark. J Antimicrobial Chemotherapy 2009; 63(2): 406-8.
168. Savard P, Gopinath R, Zhu W, et al. First NDM-positive Salmonella sp. strain identified in the United States. Antimicrob. Agents Chemother 2011; 55(12): 5957-8.
169. Koningstein M, Simonsen J, Helms M, Mølbak K. The interaction between prior antimicrobial drug exposure and resistance in human Salmonella infections. The J Antimicrobial Chemotherapy 2010; 65(8): 1819-25.
170. Smith ER, Badley BWD. Treatment of Salmonella enteritis and its effect on the carrier state. Canadian Med Association J 1971; 104: 1004-6.
171. Eloe-Fadrosh EA, McArthur MA, Seekatz AM, et al. Impact of oral typhoid vaccination on the human gut microbiota and correlations with s. Typhi-specific immunological responses. PloS One 2013; 8(4): e62026.
172. Lawley TD, Bouley DM, Hoy YE, Gerke C, Relman DA, Monack DM. Host transmission of Salmonella enterica serovar Typhimurium is controlled by virulence factors and indigenous intestinal microbiota. Infect. Immun 2008; 76(1): 403-16.
173. Hapfelmeier S, Hardt W-D. A mouse model for S. typhimuriuminduced enterocolitis. Trends Microbiol 2005; 13(10): 497-503.
174. Endt K, Stecher B, Chaffron S, et al. The microbiota mediates pathogen clearance from the gut lumen after non-typhoidal Salmonella diarrhea. Stebbins CE, editor. PloS Pathogens. Public Library Sci 2010; 6(9): e1001097.